<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Exercise and type 2 diabetes: American College of Sports Medicine and the American Diabetes Association: joint position statement.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Sports Medicine, American Diabetes Association. Exercise and type 2 diabetes: American College of Sports Medicine and the American Diabetes Association: joint position statement. Med Sci Sports Exerc. 2010 Dec;42(12):2282-303. [295 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21084931&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Abnormal glucose tolerance of mother, unspecified as to episode of care or not applicable  (648.80); Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled  (250.10); Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled  (250.60); Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled  (250.50); Diabetes with other coma, type II or unspecified type, not stated as uncontrolled  (250.30); Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled  (250.70); Hypoglycemia, unspecified  (251.2); Resistive exercise  (93.13); Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified  (249.40)"/><FieldValue Value="MSH: Diabetes Complications ; Diabetes Mellitus, Type 2 ; Diabetes, Gestational ; Diabetic Angiopathies ; Diabetic Foot ; Diabetic Nephropathies ; Diabetic Neuropathies ; Diabetic Retinopathy ; Exercise ; Hypoglycemia ; Insulin Resistance ; Medication Therapy Management ; Prediabetic State ; Range of Motion, Articular ; Resistance Training "/><FieldValue Value="MTH: Complications of Diabetes Mellitus ; Diabetes Mellitus, Non-Insulin-Dependent ; Diabetic Foot ; Diabetic Nephropathy ; Diabetic Neuropathies ; Diabetic Retinopathy ; Exercise ; Gestational Diabetes ; Hypoglycemia ; Insulin Resistance ; Prediabetes syndrome ; Range of Motion, Articular ; Resistance Training "/><FieldValue Value="PDQ: hypoglycemia "/><FieldValue Value="SNOMEDCT_US: Aerobic exerciser  (705203004); Aerobic exercises  (229072005); Diabetic complication  (74627003); Diabetic foot  (280137006); Diabetic foot examination  (401191002); Diabetic neuropathy  (230572002); Diabetic renal disease  (127013003); Diabetic retinopathy  (4855003); Drug resistance to insulin  (48606007); Examination of foot  (284384005); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Exerciser  (111045004); Foot care  (385955003); Gestational diabetes mellitus  (11687002); Hypoglycemia  (237630007); Hypoglycemia  (271327008); Hypoglycemia  (302866003); Range of joint movement  (364564000); Resistive exercise  (40454005); Type 2 diabetes mellitus  (44054006)"/><FieldValue Value="UMD: Exercisers  (11-623); Exercisers, Aerobic  (24-688); Exercisers, Flexibility  (23-508)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Type 2 diabetes mellitus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gestational diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prediabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Insulin resistance &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetes complications &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Preventive Medicine" /><FieldValue Value="Sports Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Dietitians" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To provide recommendations for the prevention and management of type 2 diabetes mellitus (T2DM) with physical activity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To discuss the benefits of physical training, along with recommendations for varying activities, physical activity-associated blood glucose management, diabetes prevention, gestational diabetes, and safe and effective practices for physical activity with diabetes-related complications &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with type 2 diabetes mellitus, gestational diabetes, prediabetes, and/or diabetes complications&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Preexercise evaluation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aerobic exercise training &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Resistance exercise training &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Combined aerobic and resistance training &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Daily movement (unstructured activity) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Flexibility training &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medication dosage adjustments as required to prevent exercise-induced hypoglycemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Daily inspection of feet and use of proper footwear &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Blood glucose control &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rates of type 2 diabetes mellitus, high blood pressure, cardiovascular events, and mortality associated with type 2 diabetes mellitus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood lipids, insulin action, fat oxidation and storage, and blood pressure responses to physical activity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Body weight loss in response to physical activity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient compliance with exercise program &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The main database searched for articles was PubMed. Literature searches were conducted from January through August 2009. Searches included all evidence-based studies from about 1990 to 2009, although most of what is cited in the position statement was published from 2000 onward.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;American College of Sports Medicine (ACSM) Evidence Categories&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table: American College of Sports Medicine (ACSM) Evidence Categories&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Evidence Category&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Source of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized, controlled trials (overwhelming data)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Provides a consistent pattern of findings with substantial studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized, controlled trials (limited data)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Few randomized trials exist, which are small in size and results are inconsistent &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Nonrandomized trials, observational studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Outcomes are from uncontrolled, nonrandomized, and/or observational studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Panel consensus judgment&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Panel's expert opinion when the evidence is insufficient to place it in categories A&amp;ndash;C&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;American Diabetes Association (ADA) Evidence-Grading System for Clinical Practice Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table: American Diabetes Association (ADA) Evidence-Grading System for Clinical Practice Recommendations&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Description&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Clear evidence from well-conducted, generalizable, randomized controlled trials that are adequately powered, including the following:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a well-conducted multicenter trial &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a meta-analysis that incorporated quality ratings in the analysis &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            Compelling nonexperimental evidence, i.e., the &quot;all-or-none&quot; rule developed by the Centre for Evidence-Based Medicine at Oxford&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Supportive evidence from well-conducted randomized controlled trials that are adequately powered, including the following:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a well-conducted trial at one or more institutions &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a meta-analysis that incorporated quality ratings in the analysis &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Supportive evidence from well-conducted cohort studies, including the following:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a well-conducted prospective cohort study or registry &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a well-conducted meta-analysis of cohort studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            Supportive evidence from a well-conducted case&amp;ndash;control study &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Supportive evidence from poorly controlled or uncontrolled studies, including the following:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Evidence from observational studies with high potential for bias (such as case series with comparison to historical controls) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Evidence from case series or case reports &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            Conflicting evidence with the weight of evidence supporting the recommendation &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;E&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert consensus or clinical experience&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Published cost analyses were reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This joint position statement was written by the American College of Sports Medicine and the American Diabetes Association and was approved by the Executive Committee of the American Diabetes Association in July 2010. This pronouncement was reviewed by the American College of Sports Medicine Pronouncements Committee, American Diabetes Association Professional Practice Committee, and by Gregory D. Cartee, Ph.D., FACSM; Peter A. Farrell, Ph.D., FACSM; Laurie J. Goodyear, Ph.D., FACSM; and Andrea M. Kriska, Ph.D., FACSM.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The American College of Sports Medicine (ACSM) levels of evidence (A-D) and American Diabetes Association (ADA) levels of evidence (A-C, E) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Acute Effects of Exercise&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Fuel Metabolism during Exercise&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Physical activity (PA) causes increased glucose uptake into active muscles balanced by hepatic glucose production, with a greater reliance on carbohydrate to fuel muscular activity as intensity increases. &lt;em&gt;ACSM evidence category A&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Insulin-stimulated blood glucose (BG) uptake into skeletal muscle predominates at rest and is impaired in type 2 diabetes mellitus (T2DM), while muscular contractions stimulate BG transport via a separate additive mechanism not impaired by insulin resistance or T2DM. &lt;em&gt;ACSM evidence category A&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Postexercise Glycemic Control/BG Levels&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Although moderate aerobic exercise improves BG and insulin action acutely, the risk of exercise-induced hypoglycemia is minimal without use of exogenous insulin or insulin secretagogues. Transient hyperglycemia can follow intense PA. &lt;em&gt;ACSM evidence category C&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The acute effects of resistance exercise in T2DM have not been reported, but result in lower fasting BG levels for at least 24 h after exercise in individuals with impaired fasting glucose (IFG). &lt;em&gt;ACSM evidence category C&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A combination of aerobic and resistance exercise training may be more effective in improving BG control than either alone; however, more studies are needed to determine if total caloric expenditure, exercise duration, or exercise mode is responsible. &lt;em&gt;ACSM evidence category B&lt;/em&gt;. Milder forms of exercise (e.g., tai chi, yoga) have shown mixed results. &lt;em&gt;ACSM evidence category C&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Insulin Resistance&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;PA can result in acute improvements in systemic insulin action lasting from 2 to 72 h. &lt;em&gt;ACSM evidence category A&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Chronic Effects of Exercise Training&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Metabolic Control: BG Levels and Insulin Resistance&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Both aerobic and resistance training improve insulin action, BG control, and fat oxidation and storage in muscle. &lt;em&gt;ACSM evidence category B&lt;/em&gt;. Resistance exercise enhances skeletal muscle mass. &lt;em&gt;ACSM evidence category A&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Lipids and Lipoproteins&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Blood lipid responses to training are mixed but may result in a small reduction in low-density lipoprotein cholesterol (LDL-C) with no change in high-density lipoprotein cholesterol (HDL-C) or triglycerides. Combined weight loss and PA may be more effective than aerobic exercise training alone on lipids. &lt;em&gt;ACSM evidence category C&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hypertension&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Aerobic training may slightly reduce systolic blood pressure (BP), but reductions in diastolic BP are less common in individuals with T2DM. &lt;em&gt;ACSM evidence category C&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Mortality and Cardiovascular Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Observational studies suggest that greater PA and fitness are associated with a lower risk of all-cause and cardiovascular (CV) mortality. &lt;em&gt;ACSM evidence category C&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Body Weight: Maintenance and Loss&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommended levels of PA may help produce weight loss. However, up to 60 min&amp;middot;d&lt;sup&gt;-1&lt;/sup&gt; may be required when relying on exercise alone for weight loss. &lt;em&gt;ACSM evidence category C&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Supervision of Training&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Individuals with T2DM engaged in supervised training exhibit greater compliance and BG control than those undertaking exercise training without supervision. &lt;em&gt;ACSM evidence category B&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Psychological Effects&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Increased PA and physical fitness can reduce symptoms of depression and improve health-related quality of life (QOL) in those with T2DM. &lt;em&gt;ACSM evidence category B&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;PA and Prevention of T2DM&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At least 2.5 h&amp;middot;wk&lt;sup&gt;-1&lt;/sup&gt; of moderate to vigorous PA should be undertaken as part of lifestyle changes to prevent T2DM onset in high-risk adults. &lt;em&gt;ACSM evidence category A. ADA A level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;PA and Prevention and Control of Gestational Diabetes (GDM)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Epidemiologic studies suggest that higher levels of PA may reduce risk of developing GDM during pregnancy. &lt;em&gt;ACSM evidence category C&lt;/em&gt;. Randomized controlled trials (RCTs) suggest that moderate exercise may lower maternal BG levels in GDM. &lt;em&gt;ACSM evidence category B&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Preexercise Evaluation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Before undertaking exercise more intense than brisk walking, sedentary persons with T2DM will likely benefit from an evaluation by a physician. Electrocardiogram (ECG) exercise stress testing for asymptomatic individuals at low risk of coronary artery disease (CAD) is not recommended but may be indicated for higher risk. &lt;em&gt;ACSM evidence category C. ADA C level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommended PA Participation for Persons with T2DM&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Aerobic Exercise Training&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Persons with T2DM should undertake at least 150 min&amp;middot;wk&lt;sup&gt;-1&lt;/sup&gt; of moderate to vigorous aerobic exercise spread out during at least 3 d during the week, with no more than two consecutive days between bouts of aerobic activity. &lt;em&gt;ACSM evidence category B. ADA B level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Resistance Exercise Training&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In addition to aerobic training, persons with T2DM should undertake moderate to vigorous resistance training at least 2&amp;ndash;3 d&lt;sup&gt;.&lt;/sup&gt;wk&lt;sup&gt;-1&lt;/sup&gt;. &lt;em&gt;ACSM evidence category B. ADA B level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Flexibility Training&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Supervised and combined aerobic and resistance training may confer additional health benefits, although milder forms of PA (like yoga) have shown mixed results. Persons with T2DM are encouraged to increase their total daily unstructured PA. Flexibility training may be included but should not be undertaken in place of other recommended types of PA. &lt;em&gt;ACSM evidence category B. ADA C level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Exercise with Nonoptimal BG Control&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Individuals with T2DM may engage in PA, using caution when exercising with BG levels exceeding 300 mg&amp;middot;dL&lt;sup&gt;-1&lt;/sup&gt; (16.7 mmol&amp;middot;L&lt;sup&gt;-1&lt;/sup&gt;) without ketosis, provided they are feeling well and are adequately hydrated. &lt;em&gt;ACSM evidence category C. ADA E level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Persons with T2DM not using insulin or insulin secretagogues are unlikely to experience hypoglycemia related to PA. Users of insulin and insulin secretagogues are advised to supplement with carbohydrate as needed to prevent hypoglycemia during and after exercise. &lt;em&gt;ACSM evidence category C. ADA C level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Medication Effects on Exercise Responses&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Medication dosage adjustments to prevent exercise-associated hypoglycemia may be required by individuals using insulin or certain insulin secretagogues. Most other medications prescribed for concomitant health problems do not affect exercise, with the exception of beta-blockers, some diuretics, and statins. &lt;em&gt;ACSM evidence category C. ADA C level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Exercise with Long-Term Complications of Diabetes&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Known cardiovascular disease (CVD) is not an absolute contraindication to exercise. Individuals with angina classified as moderate or high risk should likely begin exercise in a supervised cardiac rehabilitation program. PA is advised for anyone with peripheral artery disease (PAD). &lt;em&gt;ACSM evidence category C. ADA C level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Individuals with peripheral neuropathy and without acute ulceration may participate in moderate weight-bearing exercise. Comprehensive foot care including daily inspection of feet and use of proper footwear is recommended for prevention and early detection of sores or ulcers. Moderate walking likely does not increase risk of foot ulcers or reulceration with peripheral neuropathy. &lt;em&gt;ACSM evidence category B. ADA B level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Individuals with cardiovascular autonomic neuropathy (CAN) should be screened and receive physician approval and possibly an exercise stress test before exercise initiation. Exercise intensity is best prescribed using the heart rate (HR) reserve method with direct measurement of maximal HR. &lt;em&gt;ACSM evidence category C. ADA C level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Individuals with uncontrolled proliferative retinopathy should avoid activities that greatly increase intraocular pressure and hemorrhage risk. &lt;em&gt;ACSM evidence category D. ADA E level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Exercise training increases physical function and quality of life in individuals with kidney disease and may even be undertaken during dialysis sessions. The presence of microalbuminuria per se does not necessitate exercise restrictions. &lt;em&gt;ACSM evidence category C. ADA C level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Adoption and Maintenance of Exercise by Persons with Diabetes&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Efforts to promote PA should focus on developing self-efficacy and fostering social support from family, friends, and health care providers. Encouraging mild or moderate PA may be most beneficial to adoption and maintenance of regular PA participation. Lifestyle interventions may have some efficacy in promoting PA behavior. &lt;em&gt;ACSM evidence category B. ADA B level recommendation&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;ACSM Evidence Categories&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table: American College of Sports Medicine (ACSM) Evidence Categories&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Evidence Category&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Source of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized, controlled trials (overwhelming data)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Provides a consistent pattern of findings with substantial studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized, controlled trials (limited data)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Few randomized trials exist, which are small in size and results are inconsistent &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Nonrandomized trials, observational studies&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Outcomes are from uncontrolled, nonrandomized, and/or observational studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Panel consensus judgment&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Panel's expert opinion when the evidence is insufficient to place it in categories A&amp;ndash;C&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;American Diabetes Association (ADA) Evidence-Grading System for Clinical Practice Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table: American Diabetes Association (ADA) Evidence-Grading System for Clinical Practice Recommendations&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Description&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Clear evidence from well-conducted, generalizable, randomized controlled trials that are adequately powered, including the following:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a well-conducted multicenter trial &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a meta-analysis that incorporated quality ratings in the analysis &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            Compelling nonexperimental evidence, i.e., the &quot;all-or-none&quot; rule developed by the Centre for Evidence-Based Medicine at Oxford&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Supportive evidence from well-conducted randomized controlled trials that are adequately powered, including the following:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a well-conducted trial at one or more institutions &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a meta-analysis that incorporated quality ratings in the analysis &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Supportive evidence from well-conducted cohort studies, including the following:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a well-conducted prospective cohort study or registry &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Evidence from a well-conducted meta-analysis of cohort studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            Supportive evidence from a well-conducted case&amp;ndash;control study &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Supportive evidence from poorly controlled or uncontrolled studies, including the following:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Evidence from observational studies with high potential for bias (such as case series with comparison to historical controls) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Evidence from case series or case reports &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            Conflicting evidence with the weight of evidence supporting the recommendation &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;E&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert consensus or clinical experience&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see &quot;Major Recommendations&quot;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;It is now well established that participation in regular physical activity (PA) improves blood glucose control and can prevent or delay type 2 diabetes mellitus (T2DM), along with positively affecting lipids, blood pressure, cardiovascular events, mortality, and quality of life. Structured interventions combining PA and modest weight loss have been shown to lower T2DM risk by up to 58% in high-risk populations. Most benefits of PA on diabetes management are realized through acute and chronic improvements in insulin action, accomplished with both aerobic and resistance training.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Risk of injury &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise-associated hypoglycemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For exercise more vigorous than brisk walking or exceeding the demands of everyday living, sedentary and older diabetic individuals will likely benefit from being assessed for conditions that might be associated with risk of cardiovascular disease (CVD), contraindicate certain activities, or predispose to injuries, including severe peripheral neuropathy, severe autonomic neuropathy, and preproliferative or proliferative retinopathy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Individuals with uncontrolled proliferative retinopathy should avoid activities that greatly increase intraocular pressure and hemorrhage risk. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Individuals with angina classified as moderate or high risk should likely begin exercise in a supervised cardiac rehabilitation program. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In this article, the broader term &quot;physical activity (PA)&quot; (defined as &quot;bodily movement produced by the contraction of skeletal muscle that substantially increases energy expenditure&quot;) is used interchangeably with &quot;exercise,&quot; which is defined as &quot;a subset of PA done with the intention of developing physical fitness (i.e., cardiovascular, strength, and flexibility training).&quot; The intent is to recognize that many types of physical movement may have a positive effect on physical fitness, morbidity, and mortality in individuals with type 2 diabetes mellitus. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Sports Medicine, American Diabetes Association. Exercise and type 2 diabetes: American College of Sports Medicine and the American Diabetes Association: joint position statement. Med Sci Sports Exerc. 2010 Dec;42(12):2282-303. [295 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21084931&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Dec" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American College of Sports Medicine - Medical Specialty Society" /><FieldValue Value="American Diabetes Association - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American College of Sports Medicine&lt;/p&gt;&#xD;&#xA;&lt;p&gt;American Diabetes Association&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Authors&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;American College of Sports Medicine (ACSM)&lt;/em&gt;: Sheri R. Colberg, Ph.D., FACSM (&lt;em&gt;Chair&lt;/em&gt;); Ann L. Albright, Ph.D., RD; Bryan J. Blissmer, Ph.D.; Barry Braun, Ph.D., FACSM; Lisa Chasan-Taber, Sc.D., FACSM; and Bo Fernhall, Ph.D., FACSM&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;American Diabetes Association (ADA)&lt;/em&gt;: Judith G. Regensteiner, Ph.D.; Richard R. Rubin, Ph.D.; Ronald J. Sigal, M.D., M.P.H., FRCPC&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The authors have no financial support or professional conflicts of interest to disclose related to its content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://journals.lww.com/acsm-msse/Fulltext/2010/12000/Exercise_and_Type_2_Diabetes__American_College_of.18.aspx&quot; title=&quot;Medicine and Science in Sports and Exercise Web site&quot;&gt;Medicine &amp;amp; Science in Sports &amp;amp; Exercise Web site&lt;/a&gt; and the &lt;a href=&quot;http://care.diabetesjournals.org/content/33/12/e147.short?rss=1&quot;&gt;Diabetes Care Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Also available as an EPUB document from the &lt;a href=&quot;http://journals.lww.com/acsm-msse/Fulltext/2010/12000/Exercise_and_Type_2_Diabetes__American_College_of.18.aspx&quot;&gt;Medicine &amp;amp; Science in Sports &amp;amp; Exercise Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on July 15, 2011. The information was verified by the guideline developer on July 21, 2011.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
